Citigroup Maintains Buy on ProKidney, Raises Price Target to $9
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $9.
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $9.